Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer
B Nazha, JCH Yang, TK Owonikoko - Future Oncology, 2021 - Taylor & Francis
While randomized controlled trials (RCTs) are the gold standard for evidence-based
medicine, they do not always reflect real-world patient populations, limiting their …
medicine, they do not always reflect real-world patient populations, limiting their …
[HTML][HTML] Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes
T John, A Taylor, H Wang, C Eichinger, C Freeman… - Cancer …, 2022 - Elsevier
Mutations in exons 18–21 of the epidermal growth factor receptor gene (EGFR) can confer
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …
Risk stratification using a novel nomogram for 2190 EGFR-mutant NSCLC patients receiving the first or second generation EGFR-TKI
JWC Chang, CY Huang, YF Fang, CF Chang, CT Yang… - Cancers, 2022 - mdpi.com
Simple Summary No comprehensive and simple prognostic model based on pretreatment
factors exists for patients with epidermal growth factor receptor mutation-positive (EGFRm+) …
factors exists for patients with epidermal growth factor receptor mutation-positive (EGFRm+) …
[HTML][HTML] Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018
Z Hu, M Li, Z Chen, C Zhan, Z Lin… - … Lung Cancer Research, 2019 - ncbi.nlm.nih.gov
There were many clinical studies on lung cancer in 2018. In particular, significant progress
has been made in immunotherapy and targeted therapy. Whether in small cell lung cancer …
has been made in immunotherapy and targeted therapy. Whether in small cell lung cancer …
Egfr Tyrosine Kinase Inhibitors for EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Outcomes in Asian Populations
ES Kim, B Melosky, K Park, N Yamamoto… - Future …, 2021 - Taylor & Francis
Few data are available that have compared outcomes with different EGFR tyrosine kinase
inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell …
inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell …
Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
S Wang, J Li - OncoTargets and therapy, 2019 - Taylor & Francis
The discovery that mutations in the EGFR gene are present in up to 50% of patients with
lung adenocarcinoma, and the development of highly efficacious EGFR tyrosine kinase …
lung adenocarcinoma, and the development of highly efficacious EGFR tyrosine kinase …
Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of …
HC Chang, KT Huang, CC Tseng, YM Chen… - Thoracic …, 2023 - Wiley Online Library
Background The comparative efficacies of different generation tyrosine kinase inhibitors
(TKIs) in epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung …
(TKIs) in epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung …
Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - BMC cancer, 2021 - Springer
Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
K Park, D Wan-Teck Lim, I Okamoto… - … advances in medical …, 2019 - journals.sagepub.com
Afatinib is an ErbB family blocker that is approved for the treatment of epidermal growth
factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal …
factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal …
Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a standard of
care in the first-line treatment of patients with EGFR mutation-positive metastatic non-small …
care in the first-line treatment of patients with EGFR mutation-positive metastatic non-small …